What Happened

The U.S. Senate was scheduled to hold a confirmation hearing on Sept. 24 for Heidi Overton, nominated to lead the Food and Drug Administration (FDA), the federal agency that approves drugs, oversees food safety, and regulates dietary supplements. Overton, from New Mexico, would take the helm at a moment when Congress and the administration are signaling interest in changing how the agency operates. [](#ngr-8ebb3269-dc00-421b-83b5-3b7ce57265f9)

The hearing is scheduled before the Senate Committee on Health, Education, Labor, and Pensions, with Sen. Bill Cassidy (R-LA) set to chair and Sen. Bernie Sanders (I-VT) serving as ranking member. The committee oversees federal health agencies and must approve her nomination before the full Senate can vote.

Why Does it Matter to Me

The FDA oversees pharmaceutical approvals, dietary supplements, and food safety. The agency also sets the rules for what can be sold as a dietary supplement, a market used by roughly half of all U.S. adults.

Whoever leads the agency will shape its priorities on drug pricing, food safety rules, and the regulation of dietary supplements. Those decisions affect what medicines are available, how quickly they reach patients, and what safety standards apply to the food and products Americans buy every day.

Both Sides, Now

The hearing is scheduled to examine whether Overton's record and views align with the committee's priorities, including drug pricing, food safety modernization, and the broader role of federal health regulators. Supporters of the nomination see her as capable of steering the agency through a period of change.

Rep. Gabe Vasquez (D-NM) demanded that HHS Secretary Kennedy protect Head Start programs for New Mexico children.

Congress also holds a direct check on the FDA through its power to set the agency's annual budget and pass legislation that changes what the FDA can or must do. The committee's questions during the hearing signal what lawmakers may push for once Overton, if confirmed, is in the role.

What Happens Next

Following the hearing, the Senate Health, Education, Labor, and Pensions Committee will weigh whether Overton's record and views align with its priorities on drug pricing, food safety, and the role of federal health regulators. If the committee votes to move her forward, the full Senate would then hold its own vote to confirm or reject her.

Her confirmation will likely depend on whether committee members view her as capable of balancing competing demands from Congress, industry, and public health advocates, a test that will preview broader FDA priorities for the 119th Congress. No vote date has been announced.

---

This article was generated by AI pulling from data. Each article is edited by an editor for accuracy and clarity.

---

Spot something wrong? Report an issue with this article